🔗 Share this article

While the United States proceeds with sweeping revisions to its vaccine schedules, a particular individual has emerged in a surprising turn: Høeg, a US-based sports physician and epidemiologist who rose to prominence by questioning COVID-19 vaccinations in the global health crisis and has zeroed in on potential deaths after COVID-19 vaccination in her brief tenure at the US Food and Drug Administration (FDA).

Proposed Overhauls to Childhood Immunization Schedule

Agency leaders were set to unveil major revisions to the childhood vaccination calendar in December, bringing the US with the Danish national calendar, sources say – a substantial departure that would put the US at odds with much of the global community with no evidence for improved outcomes. The planned update has been postponed until the next year.

In place of the top vaccines chief, Tracy Beth Høeg is set to present at the gathering. She was newly appointed interim head of the FDA’s CDER, the fifth person to head the center this calendar year.

Consolidating Power at the Regulatory Body

The acting appointment may indicate a closer partnership between the pharmaceutical and biologics divisions as Dr. Høeg and Dr. Prasad consolidate power at the FDA – and it suggests a greater focus upon reevaluating previously authorized vaccines at the FDA.

Dr. Høeg has frequently advocated for halting certain childhood vaccine recommendations in the US in order to be more like the Danish model, a society with comprehensive healthcare and a population approximately the population of Wisconsin’s.

In her initial statements, she has persisted in emphasizing on vaccines – usually the purview of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to medication approval.

Doubts Over Expertise

The appointee has little discernible track record in drug development, regulation or administrative roles, which has been customary for previous directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a senior adviser to the commissioner and the vaccine center since earlier this year.

“She doesn’t seem to have any of the qualifications” for leading the pharmaceutical oversight division, said a neurologist and psychiatrist. “She lacks experience running a clinical trial. She is not versed in running a sizeable institution. She has no expertise in drug approvals.”

Former heads of CBER would “grasp laws and regulations and the science of pharmaceutical innovation”, noted Dr. Janet Woodcock. “Frankly, she lacks the type of experience that prior appointees who headed the center have had.”

The drug center has an vast portfolio at the agency, Woodcock emphasized.

“Everybody just pays attention on the novel medication approvals, but the generic drug division clears a multitude of generic medications. There’s a biosimilars program, non-prescription drug unit and more, and all of those have to be supervised,” she said. “The area you overlook, that is precisely what that I always told people is going to come back to haunt you.”

There is also, a major administrative element to the job, which oversees over 5,000 staff members. “It’s a huge leadership role, if you perform it correctly,” the former official concluded.

Agency Reaction and Controversial Programs

When asked about concerns about Dr. Høeg's credentials and whether this assignment signifies more teamwork among agency officials on vaccines, a spokesperson responded that the “questions stem from inaccurate presumptions”.

“Her experience matches the responsibilities of her job,” the representative explained, noting the period Dr. Høeg spent advising the agency head on “drug safety and approval science, including predictive safety algorithms and vaccine surveillance”.

As acting director, Høeg takes over the agency head's controversial expedited review system, a disputed one-day drug-approval program that apparently troubled her predecessors. “By what process are these drugs being selected for this expedited pathway? Who makes the calls?” Howard said. “There’s a lot of secrecy going on at the agency right now.”

Broadly speaking, he said, “the Food and Drug Administration seems to be moving towards laxer regulations of most medications, aside from shots.”

Established Track Record on Vaccines

Concerning immunizations, Dr. Høeg has a more established, if troubling, history, some experts observe. She released a study using non-validated crowd-sourced reports to determine the rate of myocarditis following Covid vaccination. She advised the Florida chief medical officer Joseph Ladapo, who allegedly have altered data to indicate Covid vaccines are pose a greater threat than they are.

Among her “wish list” for the new administration featured altering rules for new vaccines and discontinuing “unnecessary” immunizations, she said following the vote on a online show. At the agency, Dr. Høeg has allegedly proposed excluding adolescent males from obtaining COVID-19 vaccines.

“She’s an thorough true believer who commences with her conclusions and works backwards to retrofit the evidence in a highly disingenuous, fraudulent fashion,” Howard stated.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg joined other dissenters, {like|